Cellectar Biosciences(CLRB) - 2023 Q1 - Quarterly Report

FORM 10-Q Details This report details the company's Q1 2023 financial status as a non-accelerated, smaller reporting company - Filing Type: Quarterly Report on Form 10-Q for the period ended March 31, 2023[4] - Shares outstanding as of May 2, 2023: 9,740,507 shares of common stock[7] Registrant Status | Status | Value | | :--- | :--- | | Large accelerated filer | ☐ | | Accelerated filer | ☐ | | Non-accelerated filer | ☒ | | Smaller reporting company | ☒ | | Emerging growth company | ☐ | Forward-Looking Statements This section outlines the report's forward-looking statements and cautions readers about inherent risks and uncertainties - Forward-looking statements cover business strategy, product development, clinical testing, operating results, funding, and impacts of COVID-19 and regulatory changes[11] - Readers are cautioned that actual future results may differ materially due to estimates, assumptions, and uncertainties, and should not place undue reliance on forward-looking statements[13][14] PART I. FINANCIAL INFORMATION This part presents the unaudited condensed consolidated financial statements and management's analysis for Q1 2023 Item 1. Financial Statements This section presents the unaudited condensed consolidated financial statements for the period ended March 31, 2023 Condensed Consolidated Balance Sheets The balance sheets show a decrease in total assets and an increase in total liabilities as of March 31, 2023 Condensed Consolidated Balance Sheets (Unaudited) | ASSETS | March 31, 2023 | December 31, 2022 | | :--- | :--- | :--- | | Cash and cash equivalents | $12,682,691 | $19,866,358 | | Prepaid expenses and other current assets | $1,163,745 | $663,243 | | Total current assets | $13,846,436 | $20,529,601 | | Fixed assets, net | $376,084 | $418,641 | | Right-of-use asset, net | $546,505 | $560,334 | | Long-term assets | $63,217 | $75,000 | | Other assets | $6,214 | $6,214 | | TOTAL ASSETS | $14,838,456 | $21,589,790 | | LIABILITIES AND STOCKHOLDERS' EQUITY | | | | Accounts payable and accrued liabilities | $6,904,545 | $5,478,443 | | Lease liability (current) | $51,106 | $50,847 | | Total current liabilities | $6,955,651 | $5,529,290 | | Long-term lease liability, net of current portion | $548,344 | $552,981 | | TOTAL LIABILITIES | $7,503,995 | $6,082,271 | | Preferred stock | $1,382,023 | $1,382,023 | | Common stock | $97 | $94 | | Additional paid-in capital | $194,032,651 | $193,624,445 | | Accumulated deficit | $(188,080,310) | $(179,499,043) | | Total stockholders' equity | $7,334,461 | $15,507,519 | | TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $14,838,456 | $21,589,790 | Condensed Consolidated Statements of Operations The statements of operations detail a higher net loss for Q1 2023 compared to the prior-year period Condensed Consolidated Statements of Operations (Unaudited) | COSTS AND EXPENSES | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | | :--- | :--- | :--- | | Research and development | $6,654,094 | $3,887,039 | | General and administrative | $2,051,207 | $2,253,188 | | Total costs and expenses | $8,705,301 | $6,140,227 | | LOSS FROM OPERATIONS | $(8,705,301) | $(6,140,227) | | Interest income, net | $124,034 | $430 | | NET LOSS | $(8,581,267) | $(6,139,797) | | BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE | $(0.76) | $(1.00) | | SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS | 11,261,217 | 6,110,125 | Consolidated Statements of Stockholders' Equity This statement shows changes in stockholders' equity, reflecting the net loss and stock-based compensation for Q1 2023 Consolidated Statements of Stockholders' Equity (Unaudited) | | Preferred Shares | Preferred Stock Amount | Common Shares | Common Stock Par Amount | Additional Paid-In Capital | Accumulated Deficit | Total Stockholders' Equity | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | BALANCE AT DECEMBER 31, 2022 | 111 | $1,382,023 | 9,385,272 | $94 | $193,624,445 | $(179,499,043) | $15,507,519 | | Stock-based compensation | — | — | — | — | $408,206 | — | $408,206 | | Conversion of pre-funded warrants into common shares | — | — | 355,235 | $3 | — | — | $3 | | Net loss | — | — | — | — | — | $(8,581,267) | $(8,581,267) | | BALANCE AT MARCH 31, 2023 | 111 | $1,382,023 | 9,740,507 | $97 | $194,032,651 | $(188,080,310) | $7,334,461 | Condensed Consolidated Statements of Cash Flows The cash flow statements indicate a net decrease in cash primarily driven by cash used in operating activities Condensed Consolidated Statements of Cash Flows (Unaudited) | CASH FLOWS FROM OPERATING ACTIVITIES | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | | :--- | :--- | :--- | | Net loss | $(8,581,267) | $(6,139,797) | | Cash used in operating activities | $(7,183,670) | $(5,039,783) | | CASH FLOWS FROM INVESTING ACTIVITIES | | | | Purchases of fixed assets | — | $(30,070) | | Cash used in investing activities | — | $(30,070) | | CASH FLOWS FROM FINANCING ACTIVITIES | | | | Proceeds from exercise of pre-funded warrants | $3 | — | | Cash provided by financing activities | $3 | — | | NET DECREASE IN CASH AND CASH EQUIVALENTS | $(7,183,667) | $(5,069,853) | | CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | $19,866,358 | $35,703,975 | | CASH AND CASH EQUIVALENTS AT END OF PERIOD | $12,682,691 | $30,634,122 | Notes to Condensed Consolidated Financial Statements (Unaudited) This section provides detailed disclosures supporting the financial statements, including policies and going concern uncertainty Nature of Business and Organization The company is a late-stage clinical biopharmaceutical firm focused on cancer treatment via its proprietary PDC™ platform - Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company focused on cancer treatment using its proprietary phospholipid drug conjugate (PDC™) delivery platform[36] - The company has incurred significant losses since inception, with an accumulated deficit of approximately $188.08 million as of March 31, 2023, and expects continued operating losses[30] - The company's cash balance of $12.68 million as of March 31, 2023, is expected to fund operations into Q4 2023, but additional funding is required, raising substantial doubt about its ability to continue as a going concern[30] Summary of Significant Accounting Policies This section details the accounting principles applied in preparing the financial statements Principles of Consolidation Financial statements include the company and its wholly-owned subsidiary, with intercompany transactions eliminated - Consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, with all significant intercompany accounts and transactions eliminated[39] Fixed Assets Property and equipment are stated at cost and depreciated using the straight-line method over their useful lives - Property and equipment are stated at cost and depreciated using the straight-line method over estimated useful lives (3 to 10 years)[40] - No long-lived fixed asset impairment charges were recorded during the three months ended March 31, 2023[40] Right-of-Use (ROU) Asset and Lease Liabilities The company accounts for all material leases in accordance with FASB ASC Topic 842 - The Company accounts for all material leases in accordance with FASB ASC Topic 842, Leases, with ROU Assets amortized over their estimated useful life (full lease term)[41] Stock-Based Compensation The Black-Scholes model is used to value stock option awards, with expense recognized over the service period - The Black-Scholes option-pricing model is used to calculate grant-date fair value of stock option awards, with compensation expense recognized on a straight-line basis over the service period (1 to 3 years)[42] Research and Development R&D costs are expensed as incurred, with government grants recognized as a reduction of related expenses - Research and development costs are expensed as incurred[44] - During Q1 2023, the Company received approximately $406,000 in NCI grants, reported as a reduction of R&D expenses[48] Income Taxes A full valuation allowance is provided against deferred tax assets due to historical losses and uncertainty of use - Income taxes are accounted for using the liability method[45] - No uncertain tax positions require accrual or disclosure as of March 31, 2023, and December 31, 2022[45] Fair Value of Financial Instruments & Credit Risk The carrying amounts of short-term financial instruments approximate their fair value - The carrying amounts of cash equivalents, prepaid expenses, other current assets, and accounts payable approximate their fair value due to their short-term nature[46] - Uninsured cash balances totaled approximately $12.2 million as of March 31, 2023, and $19.4 million as of December 31, 2022[46] Recently Adopted Accounting Pronouncements & Government Grants The company adopted ASU 2021-10 for government assistance disclosure and received additional NCI grant funding - Adopted ASU 2021-10 (Government Assistance) for fiscal year 2022, requiring disclosure of government assistance[47] - Awarded $1.98 million in additional NCI grant funding in September 2022 to expand the Phase 1 study of iopofosine I 131 in pediatric high-grade gliomas[47] Fair Value Financial instruments are categorized into three levels based on the observability of valuation inputs - Financial assets and liabilities are grouped into three levels based on market observability of inputs (Level 1: active market quotes, Level 2: similar assets/liabilities in active markets, Level 3: unobservable inputs)[49][51] - The carrying value of cash and cash equivalents and other current financial assets and liabilities approximates fair value due to short maturities or short-term nature[52] Stockholders' Equity This section details changes in stockholders' equity, including offerings, a reverse stock split, and outstanding warrants October 2022 Public Offering and Private Placement An October 2022 offering generated approximately $9.6 million in net proceeds - Completed a registered direct offering and concurrent private placement in October 2022, generating approximately $10.7 million in gross proceeds and $9.6 million net proceeds[56] - The offering included 3,275,153 common shares and warrants, plus 1,875,945 pre-funded warrants and warrants[56] - During Q1 2023, 355,235 pre-funded warrants were converted into common shares[56] 2022 Reverse Stock Split A 1-for-10 reverse stock split was effected in July 2022 to meet Nasdaq listing requirements - A 1-for-10 reverse stock split was effected on July 21, 2022, to meet Nasdaq listing requirements[57] Equity Distribution Agreement An equity distribution agreement allows for the sale of up to $14.5 million in common stock - An equity distribution agreement allows the sale of up to $14.5 million in common stock through Oppenheimer & Co. Inc., with a 3.0% commission[58] - The ATM program was suspended in conjunction with the October 2022 offering but remains in full force and effect[60] Common Stock Warrants This section provides a summary of outstanding common stock warrants as of March 31, 2023 Outstanding Warrants to Purchase Common Stock as of March 31, 2023 | Warrant Type | Number of Outstanding Warrants | Exercise Price | Expiration Date | | :--- | :--- | :--- | :--- | | Offering 2022 Common Warrants | 5,151,098 | $1.96 | October 25, 2027 | | 2022 Pre-Funded Warrants | 1,520,710 | $0.00001 | N/A | | June 2020 Series H Warrants | 720,796 | $12.075 | June 5, 2025 | | May 2019 Series F Warrants | 195,700 | $24.00 | May 20, 2024 | | May 2019 Series G Warrants | 201,800 | $24.00 | May 20, 2024 | | July 2018 Series E Warrants | 414,000 | $40.00 | July 31, 2023 | | October 2017 Series D Warrants | 31,085 | $178.00 | October 14, 2024 | | Total | 8,235,189 | | | Stock-Based Compensation This section details the company's stock-based compensation plans, activity, and valuation assumptions 2021 Stock Incentive Plan The 2021 Stock Incentive Plan authorizes various equity awards, with shares available for future grants - The 2021 Stock Incentive Plan authorizes grants of various equity awards, with 3,254 shares available for future grants as of March 31, 2023[61] - Stockholders approved an increase of 500,000 shares for issuance under the 2021 Plan in June 2022[62] Stock Option Activity This section summarizes stock option activity and related compensation expense for the quarter - Total unrecognized compensation cost related to unvested stock-based compensation was approximately $2.366 million as of March 31, 2023, expected to be recognized through 2026[105] - During Q1 2023, 732,500 options were granted, compared to 277,850 in Q1 2022[65] Stock Option Activity Summary | | Number of Shares Issuable Upon Exercise of Outstanding Options | Weighted Average Exercise Price | | :--- | :--- | :--- | | Outstanding at December 31, 2022 | 746,257 | $13.48 | | Granted (Q1 2023) | 732,500 | $1.68 | | Forfeited (Q1 2023) | (14,800) | $14.80 | | Outstanding at March 31, 2023 | 1,478,756 | $7.59 | | Exercisable March 31, 2023 | 370,959 | $20.06 | | Unvested, March 31, 2023 | 1,107,797 | $3.42 | Stock-Based Compensation Expense | Expense Category | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | | :--- | :--- | :--- | | Research and development | $66,195 | $41,928 | | General and administrative | $342,011 | $261,877 | | Total stock-based compensation | $408,206 | $303,805 | Assumptions Used in Determining Fair Value The fair value of stock awards is estimated using the Black-Scholes model with specific assumptions - Fair value of stock awards estimated using Black-Scholes model, amortized straight-line over service period[67] - Volatility based on historical volatility; risk-free interest rate based on U.S. Treasury yield curve; expected term uses simplified method[85][86] - Forfeitures are accounted for as they occur; no historical dividends related to stock options[87][88] Income Taxes No income tax provision was recorded due to historical losses and a full valuation allowance on deferred tax assets - No provision or benefit for federal, state, or foreign income taxes recorded for Q1 2023 or Q1 2022 due to historical losses[106] - A full valuation allowance is maintained against gross deferred tax assets due to limited operating history and uncertainty of NOL utilization[106] Net Loss Per Share Basic and diluted net loss per share are identical as all potential common stock equivalents were antidilutive - Basic and diluted net loss per share are the same due to net loss, making common stock equivalents antidilutive[109] Potentially Dilutive Securities Excluded from Diluted Net Loss Per Share | Security Type | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | | :--- | :--- | :--- | | Warrants | 6,714,479 | 1,563,381 | | Preferred shares as convertible into common stock | 111,111 | 111,111 | | Stock options | 1,478,756 | 606,470 | | Total potentially dilutive shares | 8,304,346 | 2,280,962 | Commitments and Contingencies The company does not anticipate any legal matters to have a material effect on its financial statements - The Company may be involved in legal matters, but does not anticipate material effects on financial statements[110] Leases This section details the company's operating lease for its headquarters, including terms and valuation Operating Lease Liability The company amended its headquarters lease, extending the term to April 2029 - Entered an Amended Agreement of Lease on December 30, 2022, for HQ office space in Florham Park, NJ, extending the term from March 1, 2023, to April 30, 2029[112] - Aggregate rent over the amended lease term is approximately $918,000, reduced to $893,000 after abatements[113] Discount Rate A 14% interest rate is used as the incremental borrowing rate for lease liability valuation - A 14% per annum interest rate is used as the incremental borrowing rate for evaluating the present value of the Amended Lease liability[114][121] Maturity Analysis of Leases This section provides a maturity analysis of undiscounted lease payments as of March 31, 2023 Maturity Analysis of Undiscounted Lease Payments as of March 31, 2023 | Years ending March 31, | Undiscounted Lease Payments | | :--- | :--- | | 2023 | $106,000 | | 2024 | $132,000 | | 2025 | $147,000 | | 2026 | $150,000 | | 2027 | $153,000 | | Thereafter | $207,000 | | Total undiscounted lease payments | $895,000 | | Less: Imputed interest | $(295,000) | | Present value of lease liabilities | $600,000 | Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Management discusses the company's financial performance, business strategy, clinical pipeline, and liquidity Overview of Business and Strategy The company is a late-stage biopharmaceutical firm developing cancer treatments via its proprietary PDC™ delivery platform Company Overview and PDC Platform The company's PDC™ platform enables selective delivery of oncologic payloads to cancer cells - Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on cancer treatment using its proprietary phospholipid drug conjugate (PDC™) delivery platform[36][119] - The PDC platform is designed for selective delivery of diverse oncologic payloads to cancer cells, leveraging a metabolic pathway utilized by nearly all tumor cell types[132][133] - The platform aims to improve the therapeutic index of oncologic drugs by enhancing delivery to cancerous cells and cancer stem cells while minimizing exposure to healthy cells[133] Iopofosine I 131 Clinical Pipeline The lead therapeutic, iopofosine I 131, is being evaluated in multiple clinical studies for various cancers CLOVER-WaM: Phase 2 Pivotal Study in WM The CLOVER-WaM pivotal study is evaluating iopofosine in relapsed or refractory Waldenstrom's Macroglobulinemia - CLOVER-WaM is a single-arm, pivotal study in WM patients who have received and relapsed or were refractory to two prior lines of therapy, including BTKi failure[143] - The study aims to enroll 50 WM patients, with a primary endpoint of major response rate (MRR) defined as ≥50% reduction in IgM[144] - An interim safety and futility evaluation on the first 10 patients determined the study exceeded the futility threshold, allowing enrollment to continue[144] CLOVER-1: Phase 2 Study in B-Cell Malignancies The CLOVER-1 study evaluated iopofosine in various B-cell malignancies, showing promising response rates - The CLOVER-1 Phase 2 study evaluated iopofosine in select B-cell malignancies; study arms for most indications were closed as of March 2022, with MM and CNSL expansion ongoing[137][145] - In r/r WM cohort, current data show 100% ORR in 6 patients and 83.3% major response rate[149] - In r/r MM, a 40% ORR was observed in triple class refractory patients receiving >60 mCi TBD[90][91] - In r/r NHL, patients receiving ≥60mCi TBD had a 43% ORR, with DLBCL patients showing a 30% ORR[92] - Common adverse events across CLOVER-1 were fatigue (39%) and cytopenias (thrombocytopenia 75%, anemia 61%, neutropenia 54%)[147] CLOVER-2: Phase 1 Study in Pediatric Cancers The CLOVER-2 study evaluates iopofosine in pediatric patients with r/r cancers, including high-grade gliomas - CLOVER-2 Phase 1a pediatric study evaluated iopofosine safety and tolerability in children and adolescents with r/r malignant solid tumors, lymphomas, or brain tumors[127][138] - The Phase 1b study is initiating to determine appropriate dosing in pediatric patients with r/r high-grade gliomas (HGGs), supported by a $1.9M NCI SBIR Phase 2 grant[155] - Clinical data confirmed iopofosine crosses the blood-brain barrier and is delivered into pediatric brain tumors, showing disease control in heavily pretreated patients[155] - Adverse events in pediatric studies included fatigue, headache, nausea, vomiting (28% each), and cytopenias (thrombocytopenia 67%, anemia 67%)[155] Phase 1 Study in Head and Neck Cancer A Phase 1 study is assessing iopofosine combined with external beam radiation for recurrent head and neck cancer - UWCCC initiated a Phase 1 clinical study combining iopofosine and external beam radiation treatment (EBRT) for recurrent HNC, with Part A suggesting safety and tolerability[1] - Part B of the study, assessing safety and benefits in up to 24 patients, has fully enrolled[1] - The reduction in EBRT fractions with iopofosine has the potential to diminish severe adverse events associated with traditional EBRT[1] Preclinical Pipeline and Collaborations The preclinical pipeline includes chemotherapeutic and alpha-emitter radiotherapeutic programs advanced through collaborations - The preclinical pipeline includes CLR 1900 Series (chemotherapeutic for solid tumors) and CLR 12120 Series (alpha-emitter radiotherapeutic)[130][159][160] - Collaborations with IntoCell Inc. and LegoChemBio have led to selecting highly potent cytotoxic small molecule payloads[68] - A collaboration with Orano Med successfully validated the potential of PDC radio-conjugates with an alpha emitter (lead 212), demonstrating significant tumor volume reduction in animal models[159] Regulatory Designations Iopofosine has received multiple Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA - Iopofosine has Fast Track Designation for LPL/WM, r/r MM, and r/r DLBCL[128][139] - Orphan Drug Designations (ODDs) granted for LPL/WM, MM, neuroblastoma, osteosarcoma, rhabdomyosarcoma, and Ewing's sarcoma in the U.S. and for r/r MM and WM in Europe[128][139] - Rare Pediatric Disease Designation (RPDD) granted for neuroblastoma, rhabdomyosarcoma, Ewing's sarcoma, and osteosarcoma, potentially leading to a Priority Review Voucher (PRV)[128][140][156] - European Medicines Agency (EMA) granted Small and Medium-Sized Enterprise (SME) status, providing significant financial incentives[129] Results of Operations This section analyzes changes in operating expenses for Q1 2023 compared to Q1 2022 Research and Development Expense R&D expenses increased by 71% due to pivotal trial activities, manufacturing, and personnel costs - Overall R&D expense increased by approximately $2.767 million (71%) primarily due to increased clinical project costs for the pivotal trial, higher manufacturing costs, and increased personnel[72] Research and Development Expense Comparison (Q1 2023 vs. Q1 2022) | Category | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | Variance | | :--- | :--- | :--- | :--- | | Clinical project costs | $2,625,000 | $1,452,000 | $1,173,000 | | Manufacturing and related costs | $1,914,000 | $1,090,000 | $824,000 | | Pre-clinical project costs | $183,000 | $60,000 | $123,000 | | General research and development costs | $1,932,000 | $1,285,000 | $647,000 | | Total research and development | $6,654,000 | $3,887,000 | $2,767,000 | General and Administrative Expense G&A expenses decreased by 9% primarily due to lower professional fees - Overall G&A expense decreased by $202,000 (9%) primarily due to a decrease in professional fees, partially offset by an increase in personnel costs[73] General and Administrative Expense Comparison (Q1 2023 vs. Q1 2022) | Category | Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | | :--- | :--- | :--- | | General and administrative expense | $2,051,000 | $2,253,000 | Liquidity and Capital Resources The company's cash is expected to fund operations into Q4 2023, raising going concern uncertainty - The company incurred a net loss of approximately $8.6 million and used $7.2 million in cash for operations during Q1 2023, with an accumulated deficit of $188.08 million[30][74] - Consolidated cash balance was approximately $12.7 million as of March 31, 2023, expected to fund operations into Q4 2023[74] - Additional funding is required to execute the operating plan beyond Q4 2023, raising substantial doubt about the company's ability to continue as a going concern[30][74] - The COVID-19 pandemic has caused material delays in patient recruitment and enrollment for clinical studies[124] Item 3. Quantitative and Qualitative Disclosures about Market Risk As a smaller reporting company, these disclosures are not required - As a smaller reporting company, the registrant is not required to provide quantitative and qualitative disclosures about market risk[75] Item 4. Controls and Procedures Management confirms the effectiveness of disclosure controls and procedures as of the quarter-end Evaluation of Disclosure Controls and Procedures Management concluded that disclosure controls and procedures were effective as of March 31, 2023 - Management concluded that disclosure controls and procedures were effective as of March 31, 2023, ensuring timely and accurate reporting of required information[77] Changes in Internal Control Over Financial Reporting No significant changes in internal control over financial reporting occurred during the quarter - No significant changes in internal control over financial reporting occurred during the quarter ended March 31, 2023[78][79] Important Considerations Any control system provides only reasonable, not absolute, assurance due to inherent limitations - Any system of controls provides only reasonable, not absolute, assurance due to inherent limitations such as cost, judgment, human error, and fraud risk[80] PART II. OTHER INFORMATION This part covers legal proceedings, risk factors, other information, and exhibits Item 1. Legal Proceedings The company resolved a lawsuit concerning intellectual property, securing a non-exclusive license to the disputed patents - Lawsuit against Dr. Jamey Weichert and Dr. Anatoly Pinchuk regarding diverted intellectual property was resolved in November 2022[83] - All claims were dismissed, and Cellectar secured an irrevocable, non-exclusive license to the patents at issue[83] Item 1A. Risk Factors This section refers readers to the comprehensive risk factors disclosed in the company's 2022 Annual Report - Readers are directed to the Risk Factors section in the Annual Report on Form 10-K for the year ended December 31, 2022[84] Item 5. Other Information This section states that there is no other information to report under this item - No other information to report under this item[103] Item 6. Exhibits This section lists all exhibits filed with the report, including required officer certifications and interactive data files Exhibits Filed with Form 10-Q | Exhibit No. | Description | Filed with this Form 10-Q | | :--- | :--- | :--- | | 31.1 | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | | 31.2 | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | | 32.1 | Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | | 101 | Interactive Data Files | X | | 104 | Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit). | X | SIGNATURES The report was duly signed by the President and Chief Executive Officer on May 4, 2023 - Report signed by James V. Caruso, President and Chief Executive Officer, on May 4, 2023[173]